LINE

    Text:AAAPrint
    Sci-tech

    Trials show China's mRNA COVID-19 vaccine safe, effective

    1
    2022-01-26 08:35:33Xinhua Editor : Li Yan ECNS App Download
    A medical worker injects a dose of COVID-19 vaccine at a vaccination site of Jingcheng Hospital in Ruili City, southwest China's Yunnan Province, April 1, 2021. (Xinhua/Chen Xinbo)

    A medical worker injects a dose of COVID-19 vaccine at a vaccination site of Jingcheng Hospital in Ruili City, southwest China's Yunnan Province, April 1, 2021. (Xinhua/Chen Xinbo)

    Special: Battle Against Novel Coronavirus

    A China-developed mRNA COVID-19 vaccine has been shown to be safe, well-tolerated and effective in early-stage human trials, according to a study published Tuesday in the Lancet Microbe journal.

    The vaccine ARCoV, which encodes the SARS-CoV-2 spike protein receptor-binding domain, was jointly developed by the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Yunnan-based Walvax Biotechnology Co., Ltd.

    Researchers conducted phase one trials at a hospital in Hangzhou, Zhejiang Province, from Oct. 30 to Dec. 2, 2020. A total of 120 healthy adults aged between 18 and 59 who tested negative for SARS-CoV-2 participated in the trials, which were randomized, double-blind and placebo-controlled.

    The vaccination procedure included two jabs, and five quantities of the vaccine were evaluated in the tests: 5 micrograms, 10 micrograms, 15 micrograms, 20 micrograms and 25 micrograms.

    The study highlighted that 15 microgram doses induced the highest titers of neutralising antibodies, roughly double the antibody titers of convalescent patients with COVID-19, indicating stronger immune responses induced by the vaccine.

    The vaccine candidate in these phase one trials exhibited an acceptable safety profile and induced a strong immune response in participants. No serious adverse events were reported within 56 days after vaccination, according to the study.

    A multi-regional phase three human trial with more participants is currently underway to test the efficacy of the Chinese vaccine.

    Two mRNA vaccines, developed by Moderna and Pfizer-BioNTech, have been approved for emergency use.

    China started building a plant to manufacture the mRNA vaccine in December 2020 in the city of Yuxi, Yunnan Province. It is expected to produce 120 million doses per year in its first phase.

    According to its developers, ARCoV was manufactured as a liquid formulation and can be stored in standard refrigerated conditions (2-8 degrees Celsius), which is convenient for transportation and application.

    MorePhoto

    Most popular in 24h

    MoreTop news

    MoreVideo

    LINE
    Back to top About Us | Jobs | Contact Us | Privacy Policy
    Copyright ©1999-2022 Chinanews.com. All rights reserved.
    Reproduction in whole or in part without permission is prohibited.
    [網(wǎng)上傳播視聽節(jié)目許可證(0106168)] [京ICP證040655號(hào)]
    [京公網(wǎng)安備 11010202009201號(hào)] [京ICP備05004340號(hào)-1]
    主站蜘蛛池模板: 开平市| 潞西市| 天气| 厦门市| 平利县| 汉中市| 兴安盟| 青冈县| 瑞昌市| 永定县| 宜宾县| 南宁市| 普格县| 湘乡市| 十堰市| 荔浦县| 万山特区| 承德县| 阿图什市| 鲁甸县| 潢川县| 阿城市| 隆安县| 邯郸县| 瑞丽市| 海林市| 松潘县| 潜江市| 庄河市| 疏附县| 新巴尔虎右旗| 霍州市| 无为县| 亚东县| 托克逊县| 宿州市| 新乡市| 济宁市| 扶沟县| 谷城县| 新田县|